Background: Acetaminophen is an analgesic drug that is used safely in therapeutic doses. At high doses, it causes hepatotoxicity, resulting in hepatic necrosis. Some medications and methods are available for treatment of acetaminophen overdose. However, results are inconsistent, and suffi cient outcomes cannot always be obtained. Objective: The mechanism of action of acetaminophen has not been fully understood. It has been suggested that it exerts its effects on GABA receptors. Flumazenil has been experimentally proven to produce an antagonism on acetaminophen's analgesic effect. The purpose of this study was to determine whether fl umazenil antagonized the toxic effects of acetaminophen overdose in rats. Methods: A total of 49 Wistar albino rats weighing between 250 -350 g were used in the study. Nine rats were examined for a preliminary study, and the other rats were randomly divided into fi ve groups with eight subjects in each. Control group: Saline; Acetaminophen group: 3 g/kg acetaminophen; Experimental Group F1: 3 g/kg acetaminophen + 0.1 mg/kg fl umazenil; Experimental group F2: 3 g/kg acetaminophen + 1 mg/kg fl umazenil; Experimental group F3: 3 g/kg acetaminophen + 10 mg/kg fl umazenil. Acetaminophen was administered in a 3 ml saline solution by way of gastric catheter. Flumazenil was administered by way of intraperitoneal injections. Serum levels of acetaminophen, AST, ALT, LDH, ALP and bilirubin were recorded over a 24-hour period. Results: Serum acetaminophen levels were similar between the groups. The AST, ALT, ALP, LDH, total bilirubin and direct bilirubin levels of Group A were signifi cantly higher compared with the Group C, Group F1, Group F2 and Group F3. There was not a statistically signifi cant difference in the AST, ALT, ALP, LDH, total bilirubin or direct bilirubin levels of the fl umazenil-administered groups. Conclusion: Flumazenil's prevention of the acetaminophen-induced increase in liver enzymes is promising. There is some indication that fl umazenil could be used in treatment of acetaminophen intoxication (Tab. 2, Ref. 25). Full Text in PDF www.elis.sk.
Acetaminophen (APAP) toxicity is the most common cause of acute poisoning in the US and Europe (1) . APAP is a derivation of p-aminophenol, which is a synthetic non-opioid (2) . In therapeutic doses, 8 -10 % of APAP converts to its reactive metabolite N-acetyl benzoquinone (NAPQI). This metabolite is responsible for APAP's hepatic toxicity (2) . NAPQI can form covalent bonds with cellular proteins and thereby modify their structure and function (3) .
Severe hepatic failure occurs in 4 % of the patients who take APAP in toxic doses. Less than half of these cases result in death or liver transplantation (4) . Currently, N-acetylcysteine (NAC), a glutathione precursor, is the antidote for acetaminophen overdose (5) . Although NAC is the fi rst drug of choice for APAP overdose, it is associated with a variety of adverse effects (anaphylactic reaction, nausea, vomiting and diarrhea) (6, 7) . NAC is also not entirely protective for APAP toxicity (8) . NAC and methionine is not recommended in patients with hepatic failure symptoms because these symptoms increase hepatic encephalopathy (7) . Therefore, other agents should be examined for their effectiveness (8) .
GABA receptors take part in the conduction of antinociceptive impulses (9 -12) . Flumazenil, as a derivate of 1,4-imidazodiazepine, is an antagonist of benzodiazepines with partial agonist properties (13) . In previous study, Flumazenil was shown to be able to antagonize the acetaminophen-related antinociceptive effect (14) . These studies examined fl umazenil's potential benefi cial contribution to the reduction of APAP hepatotoxicity.
Material and method

Experiment animals
After its approval by the Institutional Animal Use and Care Committee of the University of Erciyes Medical Faculty, this study was performed in 49 adult albino Wistar rats (weight 250 -350 g). The study procedures were carried out according to the ethical guidelines of the EEC ethical regulations for animal research (European Economic Community Council 86/609; D.L. 27/01/1992, No, 116).
The rats were housed in plastic cages, eight per cage, with free access to rat food (Aytekinler, Konya, Turkey) and tap water, and maintained on a 12-hour dark/light cycle (lights on at 7:00 AM) under controlled environmental conditions (temperature: 20 °C, humidity: 4-50 %).
Experimental groups and drug doses used
Acetaminophen (Parol tablet, Atabay, Turkey) was administered in a dose of 3 g/kg by means of a gastric catheter in 3 ml saline (15) . Flumazenil (Anexate, Roche) was administered in doses of 0.1 mg/kg, 1 mg/kg and 10 mg/kg intraperitoneally (IP) (16) .
A preliminary study with nine rats was carried out with the aim of deciding when to study liver functions following acetaminophen administration. In this study, rats were randomly divided into three groups. After all groups had been given 3 g/kg of acetaminophen by means of a gastric catheter, the serum acetaminophen, AST, ALT, ALP and bilirubin levels were studied at 4, 24 and 40 hours. APAP levels were found to reach a peak at 4 hours. Liver function tests were found to reach a peak at 24 hours.
In the main experimental part of the study, the 40 rats used were randomly divided into fi ve groups with eight rats in each. Drug doses were calculated after their weights were measured. Rats were acclimated to the environment before initiation of any procedure. Acetaminophen in tablet form was powdered in a case, diluted with saline (total volume for each rat equaling 3 ml) and administered intragastrically by means of a gastric catheter. Blood samples were obtained at 24 hours.
Rats in Control Group (Group C, n = 8) were given 3 ml of saline solution (0.9 % NaCl) intragastrically by way of a gastric catheter. Rats in Acetaminophen Group (Group A, n = 8) were given 3 g/kg of acetaminophen intragastrically. Rats in Experimental Group F1 (Group F1, n = 8) were given 3 g/kg of acetaminophen intragastrically and one hour later were given 0.1 mg/ kg of Flumazenil IP. Rats in Experimental Group F2 (Group F2, n = 8) were given 3 g/kg of acetaminophen intragastrically and, one hour later, 1 mg/kg of Flumazenil IP. Rats in Experimental Group F3 (Group F3, n = 8) were given 3 g/kg of acetaminophen intragastrically and, one hour later, 10 mg/kg of Flumazenil IP.
Rats were sedated using 50 mg/kg of ketamine and 10 mg/ kg of xyilazine via an IP route 24 hours following acetaminophen administration. Intracardiac blood samples were obtained. Rats were sacrifi ced by the cervical dislocation method just after blood was drawn.
The obtained blood samples were immediately centrifuged in 5000 cycles for fi ve minutes, and serum and plasma were separated. Serum and plasma were stored at +4 ºC until transportation to the laboratory. The serum Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total and direct bilirubin (TB, DB) levels were measured using a Cobas Integra 800 analyzer (Cobas Reagents, Roche Diagnostics GmbH, D-68298 Mannheim). Plasma acetaminophen levels were measured with a Cobas Integra 400 analyzer (Cobas Reagents, Roche Diagnostics GmbH, D-68298 Mannheim) using aryl acylamidase with an enzymatic method.
Statistical analysis
Statistical analysis of the study was performed using SPSS software, version 15.0 (SPSS, Inc., Chicago, Illinois). The data distribution was assessed by way of the Kolmogorov-Smirnov test.
One-way ANOVA was used in the inter-group comparison of data with normal distribution. Statistical signifi cance was determined by the post hoc Tukey HSD test. The data obtained were reported as means (SD). Kruskal-Wallis test was used in intergroup comparison of data without normal distribution. Bonferroni correction was performed by making cross-comparisons in cases of statistical signifi cance. The obtained data were reported as median (min-max). p values <0.05 were considered statistically signifi cant.
Results
In our preliminary study, the acetaminophen level was found to reach a peak at four hours and the AST, ALT, ALP, LDH levels were found to reach a peak at 24 hours (Tab. 1).
Statistically signifi cant differences were found between groups in the observed values of AST (p < 0. The AST, ALT, LDH values were found to be signifi cantly higher in Group A compared with the Control Group and with the Experimental groups (Group F1, Group F2, Group F3) (p = 0.001). Although the AST, ALT, LDH values measured in the three groups for which fl umazenil was administered following acetaminophen (Group F1, Group F2, Group F3) were found to be higher compared with the values measured in Group C, this difference was not statistically signifi cant in paired comparisons (after Bonferroni correction) (p > 0.05) (Tab. 2). However, the AST, ALT, LDH levels were found to be higher in one rat that was given 0.1 mg/kg of fl umazenil and in one rat that was given 1 mg/kg of fl umazenil (Tab. 2).
The ALP values were signifi cantly lower in Group A than in the other groups (p < 0.05). There were no statistically signifi cant differences between Group C, Group F1, Group F2 TB (p = 0.001) and DB (p = 0.003) values measured in Group A were signifi cantly higher compared with the Control Group and the Experimental groups (Tab. 2).
When serum acetaminophen levels were compared, there was no statistically signifi cant difference between Group A, Group F1, Group F2 and Group F3 (p = 0.251) (Tab. 2).
Discussion
Acetaminophen is considered to be a predictable hepatotoxin, for which biochemical signs of liver damage will become apparent within 24 to 48 hours after the time of overdose. This hepatotoxin produces a dose-related centrilobular necrosis in the liver (3, 17) . Grypioti et al (18) reported that the elevated serum levels of hepatic AST, ALT (indicative of necrosis) and ALP (indicative of cholestasis) activities are in good agreement with the fi rst wave of liver injury observed between 20 and 40 h, and are due to the direct action of APAP on hepatocytes.
In our preliminary study, liver enzymes were found to reach a peak at 24 hours following APAP administration.
Schmidt and Dalhoff (19) reported that ALT levels above 1000 U/L were reached in all patients who had taken high dose acetaminophen. Grypioti et al (18) reported that ALT, AST and ALP values increased and that the liver changed histopathologically (grade of infl ammation and apoptosis). They observed in their rat model that hepatic injury was generated with a toxic dose (3.5 g/ kg) of acetaminophen. Iwalokun et al (20) administered a dose of 300 mg/kg of acetaminophen to mice via IP route for seven days and reported signifi cant increases in AST, ALT, LDH, ALP, TB, and DB levels in the acetaminophen group compared with the control group.
In our study, although signifi cant increases were found in serum AST, ALT, LDH, T.Bil and D.Bil levels in rats given 3 g/kg of acetaminophen compared with the Control group, a signifi cant difference was not found in serum ALP values.
APAP hepatotoxicity due to overdose is the most frequent cause of fulminant liver failure, with a mortality rate up to 90 %.
However, initiating the treatment in early stage in a good institution and performing liver transplantation in required cases decreases this frequency of mortality (21) . Research on the prevention of high dose acetaminophen-induced hepatotoxicity is currently ongoing.
Reports by others have shown that certain agents were beneficial for reducing APAP hepatotoxicity (ribose cysteine, L-cysteine glutathione mixed disulfi des and antioxidants). However, all these compounds were observed to be successful in reducing APAP hepatic toxicity only when administered prior to APAP exposure (22 -24) . Very few agents have been reported to reduce APAP hepatotoxicity when administered after APAP exposure in the manner of an antidote (NAC, S-adenosyl-L-methionine) (25) . NAC is the current clinical treatment for APAP overdose (25) . However, NAC is effective only for patients who present within hours of an acute overdose and is less effective for late-presenting patients (5).
Terneus et al (25) compared NAC and SAM (S-adenosyl-Lmethionine) use on liver functions following high dose APAP and reported that both agents showed decreased liver enzymes but had not reached the levels of the control group. In our study, it was found that 10 mg/kg of IP fl umazenil slowed the increase in liver enzymes that was related to high dose APAP hepatotoxicity better when compared to administration of 0.1 mg/kg and 1 mg/kg of fl umazenil. However, this decrease was not statistically significant. The decrease in liver enzymes in one rat in the Flumazenil 0.1 mg/kg group and in one rat in the Flumazenil 1 mg/kg group did not recede to the levels in the other rats.
Madenoglu et al (14) reported that fl umazenil antagonized the antinociceptive effect of acetaminophen in rats. However, this study proposed that fl umazenil caused an analgesic effect by using GABA receptors because the mechanism of action of paracetamol has not been fully understood. Although fl umazenil can have an effect on these receptors, another possible mechanism is that of fl umazenil's metabolization by conversion to inactivated free carboxylic acid and glucoronic acid. Eighty percent of acetaminophen is excreted from the kidney as inactivated compounds conjugated with sulfuric acid and glucuronic acid. Because an increased glucuronic acid amount related to fl umazenil indicates that more acetaminophen has become inactivated, a decrease in the amount going to the oxidase system resulting in NAPQI generation and a decrease in hepatotoxic effects are possible. However, histopathological studies at receptor and cellular levels are needed to understand these mechanisms of action.
In conclusion, our study is the fi rst to compare the effectiveness of different doses of fl umazenil in saline solution as an antidote for APAP toxicity. The effects at 24 hours of the administration of 0.1 mg/kg, 1 mg/kg and 10 mg/kg IP fl umazenil one hour after the administration of intragastric APAP on levels of AST, ALT, LDH, total bilirubin and direct bilirubin were found to be similar to the levels for those cases in which APAP was not given. These results suggest that fl umazenil, at least in our model, has some potential as an antidote for APAP toxicity.
